Pharma Journalist -

AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or…
Read More...

AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorisation in the European Union (EU) for…
Read More...

ImmunoGen Inc. announced that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients…
Read More...

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration…
Read More...

Nuance Pharma announces the Center for Drug Evaluation has approved its Investigational New Drug application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine…
Read More...

Telix Pharmaceuticals Limited announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a…
Read More...

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. announced that they have entered into definitive settlement agreements to resolve their pending litigation.  As part of the…
Read More...

Royalty Pharma plc and Arrowhead announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasdaq: ARWR) for $250 million in…
Read More...

After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, the vaccine was approved by the European…
Read More...

Oncopeptides AB (publ) announces that Pepaxti (melphalan flufenamide, also called melflufen) has been granted marketing authorization in combination with dexamethasone, by the Medicines…
Read More...